On Wednesday, Shares of Tenet Healthcare Corp (NYSE:THC), gained 2.60% to $47.39.
Tenet Healthcare Corporation stated Adjusted EBITDA of $568 million for the second quarter of 2015, an improvement of $108 million, or 23.5 percent, contrast to $460 million in the second quarter of 2014. The results for the second quarter of 2015 comprised of $16 million of Adjusted EBITDA generated by United Surgical Partners International (USPI) and Aspen Healthcare, which were attained by Tenet on June 16, 2015.
“This was another strong quarter for Tenet with EBITDA that exceeded our expectations,” said Trevor Fetter, chairman and chief executive officer. “We continued to focus on aggressive implementation of our strategy to improve care delivery and more closely align our business with key trends shaping the healthcare system. In our hospital business, we made progress on multiple planned partnerships that would assist us achieve leadership positions in our markets, in addition to plans to divest facilities. We also accomplished our joint venture with USPI, which makes us the leader in the fast-growing ambulatory surgery sector. We continue to position Tenet as a partner of choice for not-for-profit health systems, and we remain incredibly optimistic about the many opportunities to grow with new and existing partners through our acute care business, USPI and Conifer.”
Tenet Healthcare Corporation, a healthcare services company, primarily operates acute care hospitals and related healthcare facilities in the United States. It operates through two segments, Hospital Operations and Other, and Conifer. The company’s general hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies.
Shares of Alon USA Energy, Inc. (NYSE:ALJ), inclined 4.21% to $17.84, during its last trading session.
Alon USA Energy declared results for the second quarter of 2015. Net income accessible to stockholders for the second quarter of 2015 was $36.4 million, or $0.52 per share, contrast to net loss accessible to stockholders of $(7.5) million, or $(0.11) per share, for the same period last year. Not taking into account special items, Alon recorded net income accessible to stockholders of $46.4 million, or $0.67 per share, for the second quarter of 2015, contrast to net loss accessible to stockholders of $(3.4) million, or $(0.05) per share, for the same period last year.
Net income available to stockholders for the first half of 2015 was $63.3 million, or $0.91 per share, contrast to net loss accessible to stockholders of $(6.7) million, or $(0.10) per share, for the same period last year. Not taking into account special items, Alon recorded net income accessible to stockholders of $68.0 million, or $0.98 per share, for the first half of 2015, contrast to net income available to stockholders of $0.5 million, or $0.01 per share, for the same period last year.
Paul Eisman, President and CEO, commented, “We are happy with our strong results for the second quarter of 2015. The excellent performance from our refining and wholesale marketing segment was complemented by solid results from our retail segment. We were also happy to see an improvement in our asphalt business for the quarter contrast to the preceding quarter and relative to the second quarter of 2014.
Alon USA Energy, Inc. engages in refining and marketing petroleum products, primarily in the South Central, Southwestern, and Western regions of the United States. It operates in three segments: Refining and Marketing, Asphalt, and Retail.
At the end of Wednesday’s trade, Shares of Oceaneering International (NYSE:OII), gained 9.24% to $40.19.
Oceaneering International, declared the appointment of Alan R. Curtis as Senior Vice President and Chief Financial Officer. In addition to finance, tax, and accounting functions, Mr. Curtis will also be responsible for the oversight of Oceaneering’s investor relations activities, corporate development, risk administration policies, and facilities administration.
Mr. Curtis joined Oceaneering in 1995 as a Financial Controller and since December 2014 has served as Senior Vice President, Operations Support. He is a graduate of Texas A&I University with a bachelor’s degree in Accounting, a Certified Public Accountant in the State of Texas, and a Chartered Global Administration Accountant. Mr. Curtis has over 28 years of oilfield service and products industry experience.
Marvin J. Migura, Executive Vice President, stated, “Since Alan joined Oceaneering he has excelled in all of the positions he has held and progressively assumed more challenging and significantly higher responsibilities. He brings exceptional focus and knowledge of Oceaneering’s operations, financial experience, and leadership to his new role as Chief Financial Officer. These attributes will be beneficial to our daily operations, the market-driven business challenges we presently face, and our long-term growth plans.”
Oceaneering International, Inc. provides engineered services and products primarily to the offshore oil and gas industry worldwide. The company’s Remotely Operated Vehicles (ROVs) segment offers submersible vehicles for drilling support in the oil and gas industry; and subsea hardware installation, construction, pipeline inspection, survey and facilities inspection, maintenance, and repair services. As of December 31, 2014, this segment owned a fleet of 336 ROVs.
Finally, Illumina, Inc. (NASDAQ:ILMN), ended its last trade with 3.20% gain, and closed at $195.70.
Burning Rock and Illumina, declared they have reached a contract whereby Burning Rock will develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The partnership highlights the ever-increasing importance of genomics to improve healthcare in China.
In recent years NGS has evolved rapidly and is widely regarded as an essential technology for enabling precision medicine. The partnership between Burning Rock and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market by combining Illumina sequencing technology with Burning Rock’s advanced clinical application development capabilities. In particular, the two companies will work together to develop a user-friendly, oncology molecular diagnostic kit for the Chinese market. As part of the agreement, Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.
“We have been working to promote the clinical application of genomic technology in China. Oncology molecular diagnosis based on NGS, counting non-invasive testing, is being applied in the clinic and we hope to promote it as a standard practice in hospitals. As the leader in oncology molecular diagnosis, Burning Rock is now very happy to partner with Illumina, the global leader in sequencing and array-based technologies. Cooperation between our two companies will provide additional high-quality molecular diagnostic solutions in the clinical field of oncology,” said Yusheng Han, the Founder, and Chief Executive Officer of Burning Rock.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products comprise sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms comprise of HiScan and iScan systems, in addition to NextSeq 550 system that are array scanners for DNA and RNA analysis applications, counting single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
